Spyre Therapeutics Inc. Common Stock
SYREUnited States
57 filed reports · 420 financial concepts · 0 earnings calls · 0 media appearances
Filed reports
57 reports · Mar 2016 to Jun 2026Each report counts once it has at least one extracted financial fact. Also extracted from these reports: 139 commentary passages.
| Report type | Reports | Facts | Periods |
|---|---|---|---|
| Quarterly · 10-QSEC EDGAR | 37 | 3,057 | Mar 2016 to Jun 2026 |
| Annual · 10-KSEC EDGAR | 12 | 3,116 | Dec 2016 to Dec 2025 |
| Quarterly · 10-Q/ASEC EDGAR | 6 | 370 | Mar 2024 to Sep 2024 |
| Annual · 10-K/ASEC EDGAR | 2 | 360 | Dec 2023 |
Documents
| Period | Type | Period end | Published | Facts | Source |
|---|---|---|---|---|---|
| FY2026 Q2 | 10-Q | Jun 30, 2026 | Aug 4, 2026 | 1 | Open |
| FY2026 Q2 | 10-Q | Jun 30, 2026 | Aug 4, 2026 | 246 | Open |
| FY2026 Q1 | 10-Q | Mar 31, 2026 | May 5, 2026 | 130 | Open |
| FY2026 Q1 | 10-Q | Mar 31, 2026 | May 5, 2026 | 1 | Open |
| FY2025 | 10-K | Dec 31, 2025 | Feb 19, 2026 | 1 | Open |
| FY2025 | 10-K | Dec 31, 2025 | Feb 19, 2026 | 672 | Open |
| FY2025 Q3 | 10-Q | Sep 30, 2025 | Nov 4, 2025 | 158 | Open |
| FY2025 Q3 | 10-Q | Sep 30, 2025 | Nov 4, 2025 | 1 | Open |
| FY2025 Q2 | 10-Q | Jun 30, 2025 | Aug 5, 2025 | 1 | Open |
| FY2025 Q2 | 10-Q | Jun 30, 2025 | Aug 5, 2025 | 88 | Open |
| FY2025 Q1 | 10-Q | Mar 31, 2025 | May 8, 2025 | 92 | Open |
| FY2025 Q1 | 10-Q | Mar 31, 2025 | May 8, 2025 | 1 | Open |
Financial data
420 concepts · 6,903 factsEach concept is one reported line item or metric. The count is how many values of it are held, across the periods shown.
Financial413 concepts · 6,790 facts · Dec 2014 to Jul 2026
- Cash and cash equivalents at carrying value59 · Dec 2014 to Jun 2026
- Comprehensive income net of tax58 · Dec 2014 to Jun 2026
- General and administrative expense (US GAAP)58 · Dec 2014 to Jun 2026
- Increase decrease in accrued liabilities and other operating liabilities58 · Dec 2014 to Jun 2026
- Increase decrease in prepaid deferred expense and other assets58 · Dec 2014 to Jun 2026
- Investment income net58 · Dec 2014 to Jun 2026
- Net income loss58 · Dec 2014 to Jun 2026
- Nonoperating income expense58 · Dec 2014 to Jun 2026
- Operating expenses (US GAAP)58 · Dec 2014 to Jun 2026
- Operating income loss58 · Dec 2014 to Jun 2026
- Share based compensation58 · Dec 2014 to Jun 2026
- Accrued contracted research and development costs56 · Dec 2015 to Jun 2026
- Stockholders equity (US GAAP)56 · Dec 2014 to Jun 2026
- Common stock shares issued55 · Dec 2015 to Jun 2026
- Other comprehensive income unrealized holding gain loss on securities arising during period net of tax55 · Sep 2015 to Jun 2026
- Other nonoperating income expense55 · Sep 2015 to Jun 2026
- Accrued liabilities and other liabilities54 · Dec 2015 to Jun 2026
- Accrued professional fees current54 · Dec 2015 to Jun 2026
- Accrued salaries current54 · Dec 2015 to Jun 2026
- Accumulated other comprehensive income loss net of tax54 · Dec 2015 to Jun 2026
- Assets54 · Dec 2015 to Jun 2026
- Assets current54 · Dec 2015 to Jun 2026
- Common stock par or stated value per share54 · Dec 2015 to Jun 2026
- Common stock shares authorized54 · Dec 2015 to Jun 2026
Segment6 concepts · 74 facts · Dec 2022 to Jun 2026
- Compensation expense excluding cost of good and service sold14 · Dec 2022 to Jun 2026
- Net income loss14 · Dec 2022 to Jun 2026
- Research and development expense14 · Dec 2022 to Jun 2026
- Segment reporting other item amount14 · Dec 2022 to Jun 2026
- Share based compensation14 · Dec 2022 to Jun 2026
- Revenue4 · Dec 2022 to Dec 2025
Product1 concepts · 39 facts · Dec 2019 to Dec 2025
- Revenue39 · Dec 2019 to Dec 2025
Segments
113 factsFigures broken down by business line, region, product or another axis the company reports on.
Statement business segments1 member · 74 facts
- Reportable74 · Dec 2022 to Jun 2026
Product or service3 members · 39 facts
- Development Fee And Royalty17 · Dec 2021 to Dec 2025
- Development Fee12 · Dec 2019 to Dec 2022
- License10 · Dec 2019 to Dec 2023
Text from filings
Management commentary and risk factors, extracted from SEC filings only.
- Earnings-release commentary130 claims from 10 reports · Sep 2024 to Jun 2026
- Management discussion (MD&A) commentary139 claims from 9 reports · Mar 2024 to Jun 2026
- Risk-factor changes24 claims from 1 reports · Dec 2025
- Risk factors141 risks from 2 annual reports · 2024 to 2025
Earnings calls
Transcripts with management claims and analyst questions, one per fiscal period.
No earnings-call transcripts for this company.
Executive media
Podcasts, interviews and conference appearances by the company's executives, with their claims.
No media appearances for this company.
Reports are counted as filed reports with at least one served fact. Counts are read from the database (last read Oct 16, 2026) and refreshed every few hours.